Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Gilead Sciences (NQ: GILD)
76.76 USD  +0.41 (+0.54%)
Official Closing Price  /  Updated: 7:54 PM EDT, Jul 6, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 7,056,500
Open 77.51
Bid (Size) 76.61 (1)
Ask (Size) 76.66 (1)
Prev. Close 76.35
Today's Range 76.07 - 77.66
52wk Range 60.89 - 85.97
Shares Outstanding 1,300,260,832
Dividend Yield 2.91%
Performance
YTD
+17.68%
+17.68%
1 Month
-0.27%
-0.27%
3 Month
-1.25%
-1.25%
6 Month
+16.92%
+16.92%
1 Year
+13.75%
+13.75%
Top News
More News
New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir... Read More
from Business Wire News Releases
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company’s investigational, novel... Read More
from Business Wire News Releases
More News
Read More
European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19
from Business Wire News Releases
Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual
from Business Wire News Releases
Should You Buy These Biotech Stocks In 2020?
from Stockmarket.com
Regeneron Nears Buy Point As Drugmaker Begins Late-Stage Covid-19 Tests
from Investor's Business Daily
Covid Report: Medical Giant Surges On Its 15-Minute Coronavirus Test
from Investor's Business Daily
Welcome To H2 2020
category Services , Pharma/Biotech , Stocks / Equities
from Blogs - TalkMarkets
Shares of Gilead Have Cooled Off: Is Now the Time to Buy?
category GILD , Market News
from Motley Fool
Gilead Sciences' COVID-19 Treatment Earns Conditional Approval in Europe
category Market News , GILD
from Motley Fool
HIV Cure Challenger CytoDyn Takes On The Gilead Sciences
category Pharma/Biotech , Healthcare , Stocks / Equities
from Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.